Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management

J Clin Med. 2022 May 17;11(10):2824. doi: 10.3390/jcm11102824.


Refractory Mycoplasma pneumoniae pneumonia (RMPP) is a severe state of M. pneumoniae infection that has attracted increasing universal attention in recent years. The pathogenesis of RMPP remains unknown, but the excessive host immune responses as well as macrolide resistance of M. pneumoniae might play important roles in the development of RMPP. To improve the prognosis of RMPP, it is mandatory to recognize RMPP in the early stages, and the detection of macrolide-resistant MP, clinical unresponsiveness to macrolides and elevated proinflammatory cytokines might be clues. Timely and effective anti-mycoplasmal therapy and immunomodulating therapy are the main strategies for RMPP.

Keywords: Mycoplasma pneumoniae; pneumonia; prediction; treatment.

Publication types

  • Review